Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Journal of Medicinal Chemistry · 12.03.2026 · 69 (5) · 5147-5165
DOI: 10.1021/acs.jmedchem.5c02272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.03.2026. Verfasst von Nicholas F Endres und 51 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Antineoplastic Agents, Drug Discovery. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
KRAS G12C is one of the most prevalent oncogenic mutations in nonsmall cell lung cancer. Herein we describe the discovery and optimization of divarasib (GDC-6036), an orally available, highly potent, and selective covalent KRAS G12C inhibitor. We demonstrate a significant noncovalent binding component of divarasib that contributes to its potency and rapid kinetics. Divarasib has greater potency and kinetics of alkylation compared with other KRAS G12C inhibitors in vitro and shows robust tumor growth inhibition in multiple KRAS G12C-positive cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California 94080, United States.
- Confluence Discovery Technologies, 4340 Duncan Ave., St. Louis, Missouri 63110, United States.
- Wuxi Apptec 288 Fu Te Zhong Lu, Wai Gaio Qiao Free Trade Zone, Shanghai 200131, China.
- Viva Biotech, No.735, Ziping Road, Pudong New Area, Shanghai 201318, China.
- Crinetics Pharmaceuticals Inc, San Diego, California 92121-4718, United States.
- Pharmaron-Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, China.
ORCID-Profile: Nicholas F Endres, Jack A Terrett, Angela Oh, Taylur P Ma, Sarah M Bronner, Joachim Rudolph, Richard Zang, John G Quinn, Matthew L Landry, Hans E Purkey
Förderung
- NIGMS NIH HHS
Zitieren
APA
Endres, N. F., Do, S., Mroue, R., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., Tran, J. C., Nguyen, L. K., Lian, Q., Ma, T. P., Garner, T., Gerosa, L., Beresini, M., Boudreau, A., Bronner, S. M., Cyr, P., Ishisoko, N., …, & Purkey, H. E. (2026). Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C. Journal of Medicinal Chemistry, 69(5), 5147-5165. https://doi.org/10.1021/acs.jmedchem.5c02272
Vancouver
Endres NF, Do S, Mroue R, Terrett JA, Saabye M, Oh A, et al. Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C. Journal of Medicinal Chemistry. 2026;69(5):5147-5165. doi:10.1021/acs.jmedchem.5c02272
BibTeX
@article{Endres2026,
author = {Endres, Nicholas F and Do, Steven and Mroue, Rana and Terrett, Jack A and Saabye, Matt and Oh, Angela and Hunsaker, Thomas and Chan, Emily and Tran, John C and Nguyen, Lan K and Lian, Qihui and Ma, Taylur P and Garner, Thomas and Gerosa, Luca and Beresini, Maureen and Boudreau, Aaron and Bronner, Sarah M and Cyr, Patrick and Ishisoko, Noriko and Izrayelit, Yevgeniy and Jiang, Fan and Kellar, Terry and La, Hank and Labadie, Sharada and Lardy, Matthew and Liu, Liling and Liu, Wendy and Miller, Sarah and Rudolph, Joachim and Plise, Emile and Sellers, Benjamin D and Shao, Cheng and Wang, Weiru and Wang, Yanguang and Wei, Wentao and Wong, Susan and Yu, Christine and Yu, Kebing and Yuen, Po-Wai and Zang, Richard and Zhang, Chenghong and Zhou, Yuhui and Zhu, Xiaoyu and Quinn, John G and Ye, Xin and Kiefer, James R and Mao, Jialin and Evangelista, Marie and Merchant, Mark and Landry, Matthew L and Malhotra, Sushant and Purkey, Hans E},
title = {Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {5},
pages = {5147--5165},
doi = {10.1021/acs.jmedchem.5c02272}
}
EUVIMED